Investors considering a purchase of Reata Pharmaceuticals Inc (RETA - Get Report) shares, but cautious about paying the going market price of $26.60/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2018 put at the $20 strike, which has a bid at the time of this writing of $1.65. Collecting that bid as the premium represents a 8.2% return against the $20 commitment, or a 17.6% annualized rate of return (at Stock Options Channel we call this the YieldBoost).Selling a put does not give an investor access to RETA's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $20 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked). So unless Reata Pharmaceuticals Inc sees its shares decline 24.6% and the contract is exercised (resulting in a cost basis of $18.35 per share before broker commissions, subtracting the $1.65 from $20), the only upside to the put seller is from collecting that premium for the 17.6% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Reata Pharmaceuticals Inc, and highlighting in green where the $20 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the May 2018 put at the $20 strike for the 17.6% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Reata Pharmaceuticals Inc (considering the last 253 trading day closing values as well as today's price of $26.60) to be 51%. For other put options contract ideas at the various different available expirations, visit the RETA Stock Options page of StockOptionsChannel.com.
More from Stocks
Stocks Fall as Tensions Flare Between China and U.S.
Stocks are falling after China condemns a U.S. Senate resolution supporting human rights in Hong Kong; President Trump again threatens to increase tariffs.
Johnson & Johnson Gets a Positive Nod From Cantor Fitzgerald
Johnson & Johnson gets a healthy financial checkup and prescription from Cantor Fitzgerald, with an initial overweight recommendation and one-year price target roughly 19% higher than current levels.
Bristol-Myers Squibb Slips on Poor Skin Cancer Trial Results
Bristol-Myers Squibb trades lower after the pharmaceutical giant reveals a recent trial involving one of its treatments for melanoma skin cancer did not meet its main objective.
Nvidia, Up 55% This Year, Is Still on Track for Further Gains
Here's how to play the chipmaker now.